Eisenmenger Syndrome Treatment Market Report Analysis 2020, Global Size, Share, Industry Growth, Business Insight, Demand, Regional Analysis, Top Company Profile, Strategy Profiling, Challenges, Key Findings 2026
SEATTLE, March 25, 2021, (PHARMIWEB) — Eisenmenger Syndrome develops due to high blood pressure in the lungs, which is known as pulmonary hypertension. Pulmonary hypertension occurs due to certain congenital heart defects that cause the blood to flow from left side of the heart to right side abnormally (left-to-right shunt). The congenital heart defects resulting in this condition include Patent ductus arteriosus (PDA), atrial septal defect (ASD), Ventricular septal defect (VSD), and Atrioventricular canal defect (AV canal). The reversal of this shunt that includes movement of blood from right side of the heart back to left side (right-to-left shunt) causes insufficient oxygen supply in the blood.
Request to view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1599
This reversal occurs due to increase in blood pressure on the right side of the heart, which causes the blood to flow back to the left side, resulting in mixing of oxygenated and deoxygenated blood, in turn less oxygen supply in the blood. Moreover, continuous high pressure in the lungs causes irreversible damage to the blood vessels, fibrosis leading to thrombus formation. These changes are termed as pulmonary vascular obstructive disease or secondary pulmonary arterial hypertension (PAH). The treatment for this condition depends on individual patient’s condition and symptoms. Generally, the treatment includes relieving the symptoms and associated co-morbidities. Medications such as calcium channel blockers, antiarrhythmic agents, and blood thinning agents are prescribed by the physician.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://bit.ly/3lRzmJ3
Eisenmenger Syndrome Treatment Market Drivers
Continuous requirement of medication are expected to fuel growth of the Eisenmenger syndrome treatment market. Eisenmenger syndrome is a chronic disease and requires medication to be taken for a long period of time. The incidence and prevalence of Eisenmenger syndrome has not been properly defined due to the highly specific nature of the condition. However, according to the National Center for Biotechnology Information (NCBI), 2010, around 8% of the patients with congenital heart disease are expected to develop Eisenmenger syndrome. According to Centers for Disease Control and Prevention (CDC), Congenital Heart Diseases affects around 1% or about 40,000 of the births per year in the U.S., 2018. Moreover, technological and healthcare advancements have made it possible to correct congenital heart defects, but responses have been poor in case of patients suffering from Eisenmenger syndrome. Absence of treatment option, which may cure the condition are expected to foster growth of the global Eisenmenger syndrome treatment market, as physicians and patients have to rely on available therapies for the treatment. Most of the medications have generic versions available in the market, which has supported the growth of the market. Presence of disease targeting therapies such as Sildenafil and Bosentan have fueled the market growth over the past years and the trend is expected to remain the same, owing to unavailability of alternative options. Moreover, combination therapies is also expected to boost the growth of the market over the forecast period. For instance, European Society of Cardiology Consensus Guidelines, 2015, suggests adoption of combination therapy (Sildenafil + Bosentan, and others) in the management of pulmonary hypertension. These factors are expected to boost growth of the market over forecast period.
Despite presence of disease targeting therapies such as Sildenafil, and Bosentan the survival prospects for patients suffering from Eisenmenger syndrome have continuously been low, and the prevalence of patients suffering from Eisenmenger syndrome has decreased in the developed economies such as North America and Europe. The main reason behind this is sophisticated surgical approach in the treatment in curing the congenital heart defects and fetal screening with echocardiography in early life for heart defects. Moreover, Actelion Pharmaceuticals, Ltd.’s drug Opsumit (macitentan) showed lower than expected results in the Phase 3 clinical trials in 2017. These factors are expected to restrain growth of the global Eisenmenger Syndrome Treatment Market.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/eisenmenger-syndrome-treatment-market-1599
Eisenmenger Syndrome Treatment Market Regional Insights
Emerging economies such as Asia Pacific and Latin America are expected to witness significant growth in the Eisenmenger Syndrome treatment market over the forecast period due to reliance on available medication for the long term treatment. Government organizations from developed regions such as North America have supported the growth of the market through spreading awareness about the condition. Organizations such as American Heart Association (AHA), Congenital Heart Information Network (C.H.I.N.), Genetic and Rare Diseases (GARD) Information Center, and National Organization for Rare Disorders (NORD) keep track of Eisenmenger syndrome and related conditions.
Key players operating in Eisenmenger syndrome treatment market include Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc., Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc., Mylan N.V., and Bayer AG.
Eisenmenger Syndrome Treatment Market Taxonomy-
The global Eisenmenger syndrome treatment market is segmented on the basis of drug type, distribution channel, and region.
By Drug Type-
- Antiarrhythmic Agents
- Blood Thinning Agents
- Endothelin Receptor Antagonist
By Distribution Channel-
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Table of Content
Global Eisenmenger Syndrome Treatment Market Research Report
Section 1: Global Eisenmenger Syndrome Treatment Industry Overview
Section 2: Global Economic Impact on Eisenmenger Syndrome Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Eisenmenger Syndrome Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Eisenmenger Syndrome Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire